drugset / Trial / NCT07423572
Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)
Phase 0
Not yet recruiting
18 enrolled
The First Affiliated Hospital of Zhejiang Chinese Medical University
NaSingle-groupOpen-labelTreatment
Summary
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)
Timeline
- Start
- 2026-02-28
- Primary completion
- 2028-02-28
- Completion
- 2029-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN3601 | Cell therapy | — | — |